The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China
Open accessAbstract
A novel coronavirus (2019-nCoV) originating in Wuhan, China presents a potential respiratory viral pandemic to the world population. Current efforts are focused on containment and quarantine of infected individuals. Ultimately, the outbreak could be controlled with a protective vaccine to prevent 2019-nCoV infection. While vaccine research should be pursued intensely, there exists today no therapy to treat 2019-nCoV upon infection, despite an urgent need to find options to help these patients and preclude potential death. Herein, I review the potential options to treat 2019-nCoV in patients, with an emphasis on the necessity for speed and timeliness in developing new and effective therapies in this outbreak. I consider the options of drug repurposing, developing neutralizing monoclonal antibody therapy, and an oligonucleotide strategy targeting the viral RNA genome, emphasizing the promise and pitfalls of these approaches. Finally, I advocate for the fastest strategy to develop a treatment now, which could be resistant to any mutations the virus may have in the future. The proposal is a biologic that blocks 2019-nCoV entry using a soluble version of the viral receptor, angiotensin-converting enzyme 2 (ACE2), fused to an immunoglobulin Fc domain, providing a neutralizing antibody with maximal breath to avoid any viral escape, while also helping to recruit the immune system to build lasting immunity. The sequence of the ACE2-Fc protein is provided to investigators, allowing its possible use in recombinant protein expression systems to start producing drug today to treat patients under compassionate use, while formal clinical trials are later undertaken. Such a treatment could help infected patients before a protective vaccine is developed and widely available in the coming months to year(s).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
A novel coronavirus from patients with pneumonia in China, 2019
Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001017 · Cited by 28,244
A pneumonia outbreak associated with a new coronavirus of probable bat origin
Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969
Chan, J. F.-W., Yuan, S., Kok, K.-H., To, K. K.-W., Chu, H., Yang, J., Xing, F., Liu, J., Yip, C. C.-Y., Poon, R. W.-S., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30154-9 · Cited by 8,944
Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus
Li, W., Moore, M. J., Vasilieva, N., Sui, J., Wong, S. K., Berne, M. A., Somasundaran, M., Sullivan, J. L., Luzuriaga, K., Greenough, T. C., et al. (2003) · Nature · doi:10.1038/nature02145 · Cited by 5,923
Isolation of a Novel Coronavirus from a Man with Pneumonia in Saudi Arabia
Zaki, A. M., van Boheemen, S., Bestebroer, T. M., Osterhaus, A. D. M. E., & Fouchier, R. A. M. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1211721 · Cited by 5,735
A Novel Coronavirus Associated with Severe Acute Respiratory Syndrome
Ksiazek, T. G., Erdman, D., Goldsmith, C. S., Zaki, S. R., Peret, T., Emery, S., Tong, S., Urbani, C., Comer, J. A., Lim, W., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030781 · Cited by 4,344
A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury
Kuba, K., Imai, Y., Rao, S., Gao, H., Guo, F., Guan, B., Huan, Y., Yang, P., Zhang, Y., Deng, W., et al. (2005) · Nature Medicine · doi:10.1038/nm1267 · Cited by 3,445
Angiotensin-converting enzyme 2 protects from severe acute lung failure
Imai, Y., Kuba, K., Rao, S., Huan, Y., Guo, F., Guan, B., Yang, P., Sarao, R., Wada, T., Leong-Poi, H., et al. (2005) · Nature · doi:10.1038/nature03712 · Cited by 2,453
Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC
Raj, V. S., Mou, H., Smits, S. L., Dekkers, D. H. W., Müller, M. A., Dijkman, R., Muth, D., Demmers, J. A. A., Zaki, A., Fouchier, R. A. M., et al. (2013) · Nature · doi:10.1038/nature12005 · Cited by 2,061
Structure of SARS Coronavirus Spike Receptor-Binding Domain Complexed with Receptor
Li, F., Li, W., Farzan, M., & Harrison, S. C. (2005) · Science · doi:10.1126/science.1116480 · Cited by 2,031
Sheahan, T. P., Sims, A. C., Leist, S. R., Schäfer, A., Won, J., Brown, A. J., Montgomery, S. A., Hogg, A., Babusis, D., Clarke, M. O., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-13940-6 · Cited by 1,738
Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings
Chu, C. M. (2004) · Thorax · doi:10.1136/thorax.2003.012658 · Cited by 1,645
Henao-Restrepo, A. M., Camacho, A., Longini, I. M., Watson, C. H., Edmunds, W. J., Egger, M., Carroll, M. W., Dean, N. E., Diatta, I., Doumbia, M., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32621-6 · Cited by 1,110
Receptor and viral determinants of SARS‐coronavirus adaptation to human ACE2
Li, W., Zhang, C., Sui, J., Kuhn, J. H., Moore, M. J., Luo, S., Wong, S., Huang, I., Xu, K., Vasilieva, N., et al. (2005) · The EMBO Journal · doi:10.1038/sj.emboj.7600640 · Cited by 988
Structural insights into coronavirus entry
(2019) · Advances in Virus Research · doi:10.1016/bs.aivir.2019.08.002 · Cited by 769
Wong, S. K., Li, W., Moore, M. J., Choe, H., & Farzan, M. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.c300520200 · Cited by 694
Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry
Wan, Y., Shang, J., Sun, S., Tai, W., Chen, J., Geng, Q., He, L., Chen, Y., Wu, J., Shi, Z., et al. (2020) · Journal of Virology · doi:10.1128/jvi.02015-19 · Cited by 662
Dyall, J., Coleman, C. M., Hart, B. J., Venkataraman, T., Holbrook, M. R., Kindrachuk, J., Johnson, R. F., Olinger, G. G., Jahrling, P. B., Laidlaw, M., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03036-14 · Cited by 660
Khan, A., Benthin, C., Zeno, B., Albertson, T. E., Boyd, J., Christie, J. D., Hall, R., Poirier, G., Ronco, J. J., Tidswell, M., et al. (2017) · Critical Care · doi:10.1186/s13054-017-1823-x · Cited by 602
Pathology and Pathogenesis of Severe Acute Respiratory Syndrome
Gu, J., & Korteweg, C. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.061088 · Cited by 592
Tripathi, N. K., & Shrivastava, A. (2019) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2019.00420 · Cited by 575
SARS — beginning to understand a new virus
Stadler, K., Masignani, V., Eickmann, M., Becker, S., Abrignani, S., Klenk, H.-D., & Rappuoli, R. (2003) · Nature Reviews Microbiology · doi:10.1038/nrmicro775 · Cited by 557
Sui, J., Li, W., Murakami, A., Tamin, A., Matthews, L. J., Wong, S. K., Moore, M. J., Tallarico, A. S. C., Olurinde, M., Choe, H., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307140101 · Cited by 550
A Randomized, Controlled Trial of ZMapp for Ebola Virus Infection
The PREVAIL II Writing Group (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604330 · Cited by 520
Glowacka, I., Bertram, S., Herzog, P., Pfefferle, S., Steffen, I., Muench, M. O., Simmons, G., Hofmann, H., Kuri, T., Weber, F., et al. (2010) · Journal of Virology · doi:10.1128/jvi.01248-09 · Cited by 495
He, Y., Zhou, Y., Liu, S., Kou, Z., Li, W., Farzan, M., & Jiang, S. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.09.106 · Cited by 403
Angiotensin-converting enzyme 2 protects from lethal avian influenza A H5N1 infections
Zou, Z., Yan, Y., Shu, Y., Gao, R., Sun, Y., Li, X., Ju, X., Liang, Z., Liu, Q., Zhao, Y., et al. (2014) · Nature Communications · doi:10.1038/ncomms4594 · Cited by 401
Clinical Management of Ebola Virus Disease in the United States and Europe
Uyeki, T. M., Mehta, A. K., Davey, R. T., Liddell, A. M., Wolf, T., Vetter, P., Schmiedel, S., Grünewald, T., Jacobs, M., Arribas, J. R., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1504874 · Cited by 368
Haschke, M., Schuster, M., Poglitsch, M., Loibner, H., Salzberg, M., Bruggisser, M., Penninger, J., & Krähenbühl, S. (2013) · Clinical Pharmacokinetics · doi:10.1007/s40262-013-0072-7 · Cited by 361
IgG Fc engineering to modulate antibody effector functions
Wang, X., Mathieu, M., & Brezski, R. J. (2018) · Protein & Cell · doi:10.1007/s13238-017-0473-8 · Cited by 356
Convalescent plasma: new evidence for an old therapeutic tool?
Marano, G., Vaglio, S., Pupella, S., Facco, G., Catalano, L., Liumbruno, G. M., & Grazzini, G. (2016) · PubMed · doi:10.2450/2015.0131-15 · Cited by 322
AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges
Gardner, M. R., Kattenhorn, L. M., Kondur, H. R., von Schaewen, M., Dorfman, T., Chiang, J. J., Haworth, K. G., Decker, J. M., Alpert, M. D., Bailey, C. C., et al. (2015) · Nature · doi:10.1038/nature14264 · Cited by 298
Svoboda, T., Henry, B., Shulman, L., Kennedy, E., Rea, E., Ng, W., Wallington, T., Yaffe, B., Gournis, E., Vicencio, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032111 · Cited by 282
Passive immunotherapy of viral infections: 'super-antibodies' enter the fray
Walker, L. M., & Burton, D. R. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.148 · Cited by 268
Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primates
Thi, E. P., Mire, C. E., Lee, A. C. H., Geisbert, J. B., Zhou, J. Z., Agans, K. N., Snead, N. M., Deer, D. J., Barnard, T. R., Fenton, K. A., et al. (2015) · Nature · doi:10.1038/nature14442 · Cited by 249
Angiotensin-converting enzyme 2 inhibits lung injury induced by respiratory syncytial virus
Gu, H., Xie, Z., Li, T., Zhang, S., Lai, C., Zhu, P., Wang, K., Han, L., Duan, Y., Zhao, Z., et al. (2016) · Scientific Reports · doi:10.1038/srep19840 · Cited by 246
Moore, M. J., Dorfman, T., Li, W., Wong, S. K., Li, Y., Kuhn, J. H., Coderre, J., Vasilieva, N., Han, Z., Greenough, T. C., et al. (2004) · Journal of Virology · doi:10.1128/jvi.78.19.10628-10635.2004 · Cited by 243
Camelid Single-Domain Antibodies: Historical Perspective and Future Outlook
Arbabi-Ghahroudi, M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01589 · Cited by 210
Kraft, C. S., Hewlett, A. L., Koepsell, S., Winkler, A. M., Kratochvil, C. J., Larson, L., Varkey, J. B., Mehta, A. K., Lyon, G. M., Friedman-Moraco, R. J., et al. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ334 · Cited by 195
Jahrling, P. B., Geisbert, J., Swearengen, J. R., Jaax, G. P., Lewis, T., Huggins, J. W., Schmidt, J. J., LeDuc, J. W., & Peters, C. J. (1996) · Imported Virus Infections · doi:10.1007/978-3-7091-7482-1_12 · Cited by 175
Elshabrawy, H. A., Coughlin, M. M., Baker, S. C., & Prabhakar, B. S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050366 · Cited by 172
Experimental Treatment of Ebola Virus Disease with TKM-130803: A Single-Arm Phase 2 Clinical Trial
Dunning, J., Sahr, F., Rojek, A., Gannon, F., Carson, G., Idriss, B., Massaquoi, T., Gandi, R., Joseph, S., Osman, H. K., et al. (2016) · PLOS Medicine · doi:10.1371/journal.pmed.1001997 · Cited by 165
Du, L., Kou, Z., Ma, C., Tao, X., Wang, L., Zhao, G., Chen, Y.-Q., Yu, F., Tseng, C.-T. K., Zhou, Y., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0081587 · Cited by 162
Cheng, V. C., Wong, S., To, K. K., Ho, P., & Yuen, K. (2020) · Journal of Hospital Infection · doi:10.1016/j.jhin.2020.01.010 · Cited by 155
Anderson, J., Schiffer, C. A., Lee, S.-K., & Swanstrom, R. I. (2008) · Handbook of experimental pharmacology · doi:10.1007/978-3-540-79086-0_4 · Cited by 135
A review on current status of antiviral siRNA
Qureshi, A., Tantray, V. G., Kirmani, A. R., & Ahangar, A. G. (2018) · Reviews in Medical Virology · doi:10.1002/rmv.1976 · Cited by 120
Liu, P., Wysocki, J. A., Souma, T., Ye, M., Ramirez, V., Zhou, B., Wilsbacher, L. D., Quaggin, S. E., BATLLE, D. C., & Jin, J. (2018) · Kidney International · doi:10.1016/j.kint.2018.01.029 · Cited by 106
Clinical course and management of SARS in health care workers in Toronto: a case series.
Avendaño, M. A., Derkach, P., & Swan, S. (2003) · Europe PMC (PubMed Central) · Cited by 99
Personal Protective Equipment: Protecting Health Care Providers in an Ebola Outbreak
Fischer, W. A., Weber, D. J., & Wohl, D. A. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.07.007 · Cited by 99
Yasui, F., Kohara, M., Kitabatake, M., Nishiwaki, T., Fujii, H., Tateno, C., Yoneda, M., Morita, K., Matsushima, K., Koyasu, S., et al. (2014) · Virology · doi:10.1016/j.virol.2014.02.005 · Cited by 91
Recombinant CD4‐IgG2 in Human Immunodeficiency Virus Type 1–Infected Children: Phase 1/2 Study
Shearer, W. T., Israel, R. J., Starr, S. E., Fletcher, C. V., Wara, D. W., Rathore, M. H., Church, J. A., Deville, J. G., Fenton, T., Graham, B., et al. (2000) · The Journal of Infectious Diseases · doi:10.1086/317622 · Cited by 78
Harnessing Fc receptor biology in the design of therapeutic antibodies
Sondermann, P., & Szymkowski, D. E. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.03.005 · Cited by 77
Repurposing host-based therapeutics to control coronavirus and influenza virus
Li, C.-C., Wang, X.-J., & Wang, H. R. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.01.018 · Cited by 72
Viral infection modulation and neutralization by camelid nanobodies
Desmyter, A., Farenc, C., Mahony, J., Spinelli, S., Bebeacua, C., Blangy, S., Veesler, D., van Sinderen, D., & Cambillau, C. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1301336110 · Cited by 63
Karakus, U., Pohl, M. O., & Stertz, S. (2019) · Journal of Virology · doi:10.1128/jvi.01357-19 · Cited by 61
Antiviral Therapy Targeting Viral Polymerase
Tsai, C., Lee, P.-Y. A., Stollar, V., et al. (2006) · Current Pharmaceutical Design · doi:10.2174/138161206776361156 · Cited by 58
Rescue of non-human primates from advanced Sudan ebolavirus infection with lipid encapsulated siRNA
Thi, E. P., Lee, A. C. H., Geisbert, J. B., Ursic-Bedoya, R. J., Agans, K. N., Robbins, M., Deer, D. J., Fenton, K. A., Kondratowicz, A. S., MacLachlan, I., et al. (2016) · Nature Microbiology · doi:10.1038/nmicrobiol.2016.142 · Cited by 58
AAV-delivered eCD4-Ig protects rhesus macaques from high-dose SIVmac239 challenges
Gardner, M. R., Fellinger, C. H., Kattenhorn, L. M., Davis-Gardner, M. E., Weber, J. A., Alfant, B., Zhou, A. S., Prasad, N. R., Kondur, H. R., Newton, W., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aau5409 · Cited by 56
Aerosol Delivery of siRNA to the Lungs. Part 1: Rationale for Gene Delivery Systems
Youngren-Ortiz, S. R., Gandhi, N. S., España‐Serrano, L., & Chougule, M. B. (2015) · KONA Powder and Particle Journal · doi:10.14356/kona.2016014 · Cited by 51
Koch, K., Kalusche, S., Torres, J. L., Stanfield, R. L., Danquah, W., Khazanehdari, K. A., von Briesen, H., Geertsma, E. R., Wilson, I. A., Wernery, U., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-08273-7 · Cited by 43
Small molecules with antiviral activity against the Ebola virus
Litterman, N. K., Lipinski, C. A., & Ekins, S. (2015) · F1000Research · doi:10.12688/f1000research.6120.1 · Cited by 33
Dodd, L. E., Follmann, D. A., Proschan, M. A., Wang, J., Malvy, D. J.-M., van Griensven, J., Ciglenečki, I., Horby, P., Ansumana, R., Jiang, J., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw1049 · Cited by 33
Biopharma CRO industry in China: landscape and opportunities
Xia, C., & Gautam, A. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.02.007 · Cited by 26
Shao, Z., Shrestha, K. L., Borowski, A. G., Kennedy, D. J., Epelman, S., Thomas, J. D., & Tang, W. H. W. (2013) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2013.06.296 · Cited by 25
Generation of therapeutic antisera for emerging viral infections
Schmidt, R., Beltzig, L. C., Sawatsky, B., Dolnik, O., Dietzel, E., Krähling, V., Volz, A., Sutter, G., Becker, S., & von Messling, V. (2018) · npj Vaccines · doi:10.1038/s41541-018-0082-4 · Cited by 14
Cited by
Human neutralizing antibodies elicited by SARS-CoV-2 infection
Ju, B., Zhang, Q., Ge, J., Wang, R., Sun, J., Ge, X., Yu, J., Shan, S., Zhou, B., Song, S., et al. (2020) · Nature · doi:10.1038/s41586-020-2380-z · Cited by 1,667
C-reactive protein levels in the early stage of COVID-19
Wang, L. (2020) · Médecine et Maladies Infectieuses · doi:10.1016/j.medmal.2020.03.007 · Cited by 686
COVID-19: A promising cure for the global panic
Vellingiri, B., Jayaramayya, K., Iyer, M., Narayanasamy, A., Govindasamy, V., Giridharan, B., Ganesan, S., Venugopal, A., Venkatesan, D., Ganesan, H., et al. (2020) · Science of The Total Environment · doi:10.1016/j.scitotenv.2020.138277 · Cited by 636
Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2
Chan, K. K., Dorosky, D., Sharma, P., Abbasi, S. A., Dye, J. M., Kranz, D. M., Herbert, A. S., & Procko, E. (2020) · Science · doi:10.1126/science.abc0870 · Cited by 632
Recent Developments on Therapeutic and Diagnostic Approaches for COVID-19
Majumder, J., & Minko, T. (2021) · The AAPS Journal · doi:10.1208/s12248-020-00532-2 · Cited by 505
Metadata
- Authors
- Kruse, R. L.
- Venue
- F1000Research
- Publisher
- F1000 Research Ltd
- Published
- 2020-01-31
- Volume
- 9
- Pages
- 72
- ISSN
- 2046-1402 (ISSN-L)
- OpenAlex
- W3004071935
- Cited by
- 311
- References
- 66
- FWCI
- 9.14
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.